Prot#WTX101-301: A Phase 3, Randomised, Rater-Blinded, Multi-Centre Study to Evaluate the Efficacy and Safety of WTX101 Administered for 48 Weeks Versus Standard of Care in Wilson Disease Subjects Aged 18 and Older with an Extension Phase of up to 60 Mont

Project: Research project

Project Details

Effective start/end date3/1/183/1/24


  • Alexion Pharmaceuticals, Inc. (Prot#WTX101-301)
  • Wilson Therapeutics AB (Prot#WTX101-301)